Zilebesiran clinical trials
Also written ALN-AGT01.
How each study uses zilebesiran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the zilebesiran studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses zilebesiran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseRecruitingPhase 3Alnylam PharmaceuticalsNCT07181109Written as Zilebesiran
- A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate HypertensionCompletedPhase 1/2Alnylam PharmaceuticalsNCT06423352Written as Zilebesiran
- Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)CompletedPhase 2Alnylam PharmaceuticalsNCT06272487Written as Zilebesiran
- A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate HypertensionCompletedPhase 2Alnylam PharmaceuticalsNCT04936035Written as ALN-AGT01
- A Study to Evaluate ALN-AGT01 in Patients With HypertensionCompletedPhase 1Alnylam PharmaceuticalsNCT03934307Written as ALN-AGT01
Given beside what is tested · 2 — zilebesiran is usual care or a partner of the new treatment
- A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With ZilebesiranRecruitingPhase 2Alnylam PharmaceuticalsNCT07553442Written as Zilebesiran
- Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)CompletedPhase 2Alnylam PharmaceuticalsNCT05103332Written as Zilebesiran
Codes
What other systems call zilebesiran · ClinicalTrials.gg INT016411
- UNII (FDA) E422BH4BRKZILEBESIRANOne source FDA
- NCI Thesaurus C179136ZilebesiranOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | E422BH4BRK | ZILEBESIRAN | One source FDA |
| NCI Thesaurus | C179136 | Zilebesiran | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.